Ryan Dunlap - 28 Oct 2024 Form 4 Insider Report for CytoDyn Inc. (CYDY)

Role
Director
Signature
/s/ Tyler Blok, Attorney-in-Fact for Ryan Dunlap
Issuer symbol
CYDY
Transactions as of
28 Oct 2024
Net transactions value
$0
Form type
4
Filing time
30 Oct 2024, 21:46:22 UTC
Previous filing
05 Jan 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CYDY Non-qualified stock option (right to buy) Award $0 +800,000 $0.000000 800,000 28 Oct 2024 Common Stock 800,000 $0.1300 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This grant was approved by the Company's Compensation Committee on October 28, 2024 and represents the annual grant awarded to the individual for fiscal year 2025. This award is made consistent with, and utilizes shares from, the Issuer's 2012 Equity Incentive Plan, as amended.
F2 266,664 shares vested on the grant date, and the balance will vest in equal monthly installments at the conclusion of each month of Continuous Service (as the term is defined in the Issuer's 2012 Equity Incentive Plan, as amended) from October 2024 through May 2025.

Remarks:

EX 24 - Power of Attorney